Abstract：Objective: To study the effect of Lung surface active substances (PS) combined with noninvasive positive pressure ventilationin treatment of Neonatal respiratory distressand its effectson blood gas index. Methods: 100 newborn patients with respiratory distress admitted to our hospital from February 2017 to February 2019 were selected for the study,by stochastic indicator method, divided into the observation group (n = 52) and control group (n = 48) and control group using noninvasive positive pressure ventilation therapy, observation group on the basis of this combined therapy with PS, comparing two groups of clinical curative effect, the hydrogen ion concentration index (pH), CO2 partial pressure (PCO2), oxygenation index (PaO2 / FiO2) level, the aeration time level of complications, length of hospital stay, hospital expenses. Results: After treatment, the total effective rate of the observation group was 90.38% higher than that of the control group (P<0.05). Before treatment, there was no significant difference in blood gas index between the two groups (P>0.05). After treatment, blood gas index levels of children in both groups were significantly improved compared with those before treatment (P<0.05). PH, PaO2/FiO2 levels of children in the observation group were significantly higher than those in the control group, and PCO2 levels were significantly lower than those in the control group (P<0.05). Ventilation time, length of stay and cost of hospitalization in the observation group were significantly lower than those in the control group (P<0.05). The total incidence of adverse reactions in the two groups was 19.23% and 43.75%, respectively, with significant differences (P<0.05). Conclusion: PS combined with non-invasive positive pressure ventilation has a significant effect in the treatment of neonatal respiratory distress, which can effectively improve the blood gas index of children, and is worthy of promotion and application.
[1] 林伟斌.肺表面活性物质联合CPAP治疗对新生儿呼吸窘迫综合征血气指标的影响[J].临床肺科杂志,2017,22(1):102~104. [2] 王文秀,陈波,章伟,等.血清高迁移率族蛋白B1与新生儿呼吸窘迫综合征的相关性研究[J].中国当代儿科杂志,2017,19(4):398~401. [3] Jesse G, Natecho Alice, Mwambeo Humphrey M, et al. Evaluating quality neonatal care, call centre service, tele-health and community engagement in reducing newborn morbidity and mortality in bungoma county, Kenya[J]. Bmc Health Services Research, 2018, 18(1):493. [4] 朱文英,袁玉峰,张海燕,等.两种无创正压通气模式联合固尔苏治疗新生儿呼吸窘迫综合征的疗效比较[J].江苏医药,2017,43(24):1826~1827. [5] 宋国维.新生儿呼吸窘迫综合征的诊治[J].中国实用儿科杂志,2008,23(7):488~490. [6] Di Mauro, Antonio, Capozza, Manuela, Cotugno, Sergio, et al. Nasal high flow therapy in very low birth weight infants with mild respiratory distress syndrome: a single center experience[J]. Italian Journal of Pediatrics, 2017, 43(1):116. [7] 韦婷艳,周结儿,王章星,等.不同剂量肺表面活性物质联合鼻塞持续正压通气治疗新生儿呼吸窘迫综合征疗效比较[J].海南医学,2017,28(19):3148~3150. [8] 邓黎静,彭华保,龚晓琴.布地奈德联合肺泡表面活性物质气管内滴入治疗早产儿重症呼吸窘迫综合症的疗效研究[J].中南医学科学杂志,2018,46(1):91~94.
2020, Vol. 26 
冀公网安备13080202000677号